Acute radiation syndrome

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

Retrieved on: 
월요일, 8월 8, 2022
Science, Stem Cells, Other Science, Biotechnology, Research, Health, Clinical Trials, Other Health, Death, Risk, Uniformed Services University of the Health Sciences, Vasculitis, Inflammation, Private Securities Litigation Reform Act, SEC, Bleeding, Clinical trial, Regenerative medicine, Policy, Annual report, Research, Department, Patient, AFRRI, Bone marrow, Company, Twitter, Department of Defense Serum Repository, Radiation, Dehydration, Partnership, Syndrome, Outline of health sciences, Edema, Acute radiation syndrome, Survivor, Social media, Infection, Investor, LinkedIn, ARS, Time, GI, Pharmaceutical industry, Facebook

ARS may be associated with destructive and irreparable changes in the bone marrow and gastrointestinal (GI) tract, resulting in infection, hemorrhage and dehydration.

Key Points: 
  • ARS may be associated with destructive and irreparable changes in the bone marrow and gastrointestinal (GI) tract, resulting in infection, hemorrhage and dehydration.
  • At lower doses a period of bone marrow damage lasting weeks which ultimately can be lethal without intervention is expected.
  • Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.
  • MultiStem therapys potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit.

DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

Retrieved on: 
목요일, 8월 4, 2022
Microsoft, Acute radiation syndrome, Infection, Radiation Sickness, Epidemic, Wastewater treatment, Subacute myelo-optic neuropathy, MCM, Nuclear medicine, National, Joint Chemical, Biological, Radiological and Nuclear Regiment, Industry, Program, Research, Commissariat, CEA, Radiation, National Institute, NATO, Medicine, ISIN, Therapy, Mortality, Toxicity, SDAX, CRBN, Deutsch, NIAID, ARS, Pharmaceutical industry, Medical imaging, EU, Chemical substance, Nuclear

The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.

Key Points: 
  • The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.
  • Beyond its potential as a medical countermeasure, the MCM portfolio has several promising clinical applications in mitigating radiation and chemotherapy-induced toxicity in nuclear medicine and (radiation) oncology.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality.

BIO 300 Pharmacokinetics Studies Published

Retrieved on: 
수요일, 7월 27, 2022
Men, Research, Other Health, General Health, Pharmaceutical, Oncology, Consumer, Clinical Trials, Science, Children, Women, Seniors, Health, Polish Radiation Research Society, University, CEO, Radiation, MCM, University of Maryland School of Medicine, Risk, UMB, COVID-19, Survivor, Cancer, ARS, Clinical trial, PK, FDA, Lung cancer, Patient, Pharmacokinetics, Acute radiation syndrome, Radiation Research, BIO, Medical imaging, Pharmacy, Humanetics

A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporations (Humanetics) new radioprotective drug, BIO 300.

Key Points: 
  • A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporations (Humanetics) new radioprotective drug, BIO 300.
  • The studies, which were conducted by researchers at the University of Maryland Schools of Medicine and Pharmacy (UMB), compared the PK of BIO 300 using oral, subcutaneous, and intramuscular dosing.
  • These nonclinical studies also examined the effect of radiation exposure on the PK of BIO 300.
  • Current events in Ukraine and global threats of nuclear incidents point to the urgent need for drugs like BIO 300.

DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development

Retrieved on: 
목요일, 7월 21, 2022
Rabbit, National, Toxicity, Mortality, Acute radiation syndrome, Deutsch, Red blood cell, Industry, Neutrophil, ISIN, NIAID, Temperature, Radiation, National Institute, MCM, RIM, Infection, Medicine, ARS, Nuclear medicine, Subacute myelo-optic neuropathy, Lymphocyte, Blood, Survival, Mouse, Gesellschaft mit beschränkter Haftung, SDAX, Radiation Sickness, CIM, Pharmaceutical industry, Medical imaging

Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.

Key Points: 
  • Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.
  • Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed Myelo001s excellent safety profile.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Brse.

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

Retrieved on: 
화요일, 5월 17, 2022
Cancer, Megaphone, Association of American Universities, Breast, Humanities, Engineering, Company, Assistant, U.S. Securities and Exchange Commission, Breast cancer, Exercise, Goal, University, OTC, TLR5, Review, Entolimod, Therapy, Learning, Association, Canadian Aviation Regulations, Research, Patent, Securities Act of 1933, Securities Exchange Act of 1934, Toxicity, SPAC, Acute radiation syndrome, Forward-looking statement, Humanitarian use licenses, Technology, Ovarian cancer, National, CAR, Acquisition, Laboratory, Security (finance), CEO, Vaccine, Pharmaceutical industry, Immunology, Chemistry

WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial cancer indications under development are pre-clinical programs targeting breast cancer and ovarian cancer. Terms of the deal were not disclosed.

Key Points: 
  • Among the initial cancer indications under development are pre-clinical programs targeting breast cancer and ovarian cancer.
  • Per the option agreement, Coeptis paid the University of Pittsburgh a non-refundable fee for the exclusive option to license the patent rights to each of the three technologies.
  • Coeptis has until October 29, 2022, to exercise the options and pay the specified exercise considerations.
  • The option agreement may be extended an additional six months, subject to the agreement of both parties.

New Studies Published Comparing BIO 300 to Neulasta® for Acute Radiation Syndrome

Retrieved on: 
화요일, 4월 26, 2022
Research, Radiology, Contracts, Pharmaceutical, Oncology, Law Enforcement, Emergency Services, Defense, Clinical Trials, Science, Biotechnology, Other Science, Health, ARS, CEO, Injury, Clinical trial, United States Department of Defense, COVID-19, BIO, International Journal of Radiation Biology, Radiobiology, Outline of health sciences, Acute radiation syndrome, Patient, Uniformed Services University of the Health Sciences, Canadian International Council, Organizational structure of the United States Department of Defense, Emergency Use Authorization, Radiation, FDA, Lung cancer, Bone marrow failure, Cancer, Survival, Medical imaging, Pharmaceutical industry, Humanetics

A recently published paper in the International Journal of Radiation Biology details results from a series of studies conducted with Humanetics Corporations (Humanetics) new radioprotective drug, BIO 300.

Key Points: 
  • A recently published paper in the International Journal of Radiation Biology details results from a series of studies conducted with Humanetics Corporations (Humanetics) new radioprotective drug, BIO 300.
  • This nonclinical research showed that giving BIO 300 prior to exposure to lethal levels of radiation improved survival equal to Neulasta, which is given after exposure.
  • Exposure to radiation can lead to acute radiation syndrome (ARS), which involves a multitude of injuries, including bone marrow failure.
  • BIO 300 is also in clinical development for oncology applications to protect cancer patients from unintentional side effects caused by radiation therapy.

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma

Retrieved on: 
수요일, 4월 13, 2022
Entolimod, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, Acute radiation syndrome, Anemia, OTC, Patient, Goal, TLR5, Karolinska Institute, Review, Technology, Hematology, Neutropenia, Nasdaq, Company, NF-κB, Apoptosis, Radiation exposure, Forward-looking statement, Reactive oxygen species, Therapy, Cancer, Pharmaceutical industry

WEXFORD, Pa. , April 13, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc. (Nasdaq: STAB) that gives Coeptis the right to acquire Statera's toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency. Coeptis and Statera have agreed to an exclusivity period through the date that is 30 days following the date on which the first draft of the definitive agreement is available to review by both parties. 

Key Points: 
  • The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
  • Entolimod is Statera's most advanced TLR5 agonist technology and is currently in development to treat acute radiation syndrome.
  • Coeptis was founded in 2017 and is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/ .
  • Additional factors are discussed in our filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov .

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Retrieved on: 
수요일, 3월 23, 2022
TASE, Therapy, Orphan, Bleeding, Mortality, IND, PGF, Patient, Food, Acute radiation syndrome, ARS, Injection, Safety, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Infection, FDA, HCT, Data, Pharmaceutical industry

Incomplete hematopoietic recovery, or poor graft function (PGF), is a life-threatening complication for patients undergoing HCT.

Key Points: 
  • Incomplete hematopoietic recovery, or poor graft function (PGF), is a life-threatening complication for patients undergoing HCT.
  • Current standard-of-care treatments do not result in satisfactory blood counts in some or all blood cell lineages.
  • Consequently, patients are vulnerable to bleeding andrecurrent infections, and require repeated costly transfusions of blood products, which only provide short-term benefits.
  • Data collated 12 months post-treatment with PLX-R18 demonstrate that:
    PLX-R18 was well-tolerated with a favorable safety profile.

Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod

Retrieved on: 
수요일, 12월 1, 2021
Patient, ARS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pancreatic cancer, Safety, Coronavirus, Cancer, TLR4, Risk, TLR5, European Union, Company, Multiple sclerosis, Exercise, Neutropenia, Virus, Autoimmunity, Homeostasis, SEC, Budget, COVID-19, Acute radiation syndrome, Fibromyalgia, Anemia, Research, GLOBE, TLR, Hematology, TLR9, Antibody, Union, FDA, Cleveland, Growth, Cleveland BioLabs, Food, Pharmaceutical industry

We are pleased that the FDAs clinical hold questions have been successfully addressed, allowing us to continue our clinical work in ARS and explore new indications for Entolimod in hematology, specifically treatment of neutropenia and anemia in cancer patients, said Michael K. Handley, President and Chief Executive Officer, Statera Biopharma.

Key Points: 
  • We are pleased that the FDAs clinical hold questions have been successfully addressed, allowing us to continue our clinical work in ARS and explore new indications for Entolimod in hematology, specifically treatment of neutropenia and anemia in cancer patients, said Michael K. Handley, President and Chief Executive Officer, Statera Biopharma.
  • We look forward to accelerating the development of Entolimod as part of our mission to introduce a new generation of immunotherapies targeting serious medical needs.
  • Based on the data demonstrating efficacy and safety in acute radiation syndrome, Statera intends to evaluate ongoing development requirements and medical needs for Entolimod.
  • Statera has clinical programs for Crohns disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis.

Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2021: COVID-19 Impact and Recovery to 2030

Retrieved on: 
화요일, 10월 12, 2021
Application, Man, Center, CT, Korea Disease Control and Prevention Agency, GE Healthcare, American Heart Association, Death, Burn, Health, Accident, CT scan, CAGR, National Council on Radiation Protection and Measurements, COVID-19, USA, Acute radiation syndrome, Radiology, Diagnosis, Canon Medical Systems Corporation, Cancer, Industry, Population, Hitachi, Samsung Electronics, Cardiology, Radiation protection, National Council, Patient safety, CVD, Radiation, Prevalence, PACS, Woman, Pathology, PET, Dermatology, NCRP, Degenerative disease, Shimadzu, DOH, Medical imaging

Effects of radiation and increasing health concerns hinders the computed tomography (CT) scanner devices and equipment market growth.

Key Points: 
  • Effects of radiation and increasing health concerns hinders the computed tomography (CT) scanner devices and equipment market growth.
  • Global Computed Tomography (CT) Scanners Devices And Equipment Forecast Market, 2020-2025F, 2030F, $ Billion
    6.1.
  • Global Computed Tomography (CT) Scanners Devices And Equipment Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
    6.2.
  • Global Computed Tomography (CT) Scanners Devices And Equipment Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion